infertility
Conditions
Interventions
In the study group, Dienogest (2mg/day 1mg tablet 2 times/day) is administered orally from the previous cycle. And trans-vaginal ultrasonography and serum hormone measurements are performed, to follow
70pg/ml. After that patients are administered human menopausal gonadotropin per day. The initiating dose of 150 IU per day is used for patients with an AMH level over 3.0 ng per ml or a high antral fo
Sponsors
Kamiya Ladies Clinic
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Endometriosis-associated infertile women who undergo IVF-ET program. 1) woman who has endometrioid cyst (chocolate cyst) (cyst diameter smaller than 4cm) diagnosed by imaging. (The patient with endometrial cysts more than 4cm receive the reduction treatment with operation or medication before IVF-ET start.) 2) woman who give written informed consent before entry into this study.
Exclusion criteria
Exclusion criteria: 1) Patients who documented cycles with no oocyte retrieved, any contraindications to ovarian stimulation treatment and 2) patients who has contraindication to DNG, GnRHa, EP, FSH, HMG, HCG 3) Patients who is judged to be inappropriate for this study by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical pregnancy rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) total amount of FSH/HMG 2) number of growing follicle (<15mm) and mature follicle (<18mm), number of oocyte retrieved 3)the incidence of premature LH surge 4) fertilization rate, implantation rate 5) serum concentration of estradiol and progesterone (on the trigger day) 6) the incidence of OHSS 7) the viable embryo rate 8) ongoing pregnancy rate, early miscarriage rate, multiple pregnancy rate | — |
Countries
Japan
Contacts
Public ContactNanako Iwami
Kamiya Ladies Clinic Reproductive therapy
Outcome results
None listed